Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cediranib plus gemcitabine/cisplatin versus placebo plus gemcitabine/cisplatin in advanced non-small cell lung cancer
2007-006250-25Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bevacizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by AstraZeneca. Primary endpoint: Progression-free survival. Started Jan 2008; status: completed.
02
Drugs
bevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2007-006250-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006250-25.